医药导报2026，Vol.45Issue(6)：1009-1014,6.DOI:10.3870/j.issn.1004-0781.2026.06.009
蛋白降解靶向嵌合体药物研究新进展
Research Progress on Proteolysis-Targeting Chimeras Drug
摘要
Abstract
Proteolysis-targeting chimeras(PROTACs)are heterobifunctional molecules composed of an E3 ubiquitin ligase ligand,a linker,and a protein of interest(POI)ligand.They function by recruiting intracellular E3 ubiquitin ligases to spe-cifically ubiquitinate the POI,thereby directing the proteasome to recognize and degrade the POI,achieving precise degradation of the POI.Compared with conventional small-molecule inhibitors,PROTACs have advantages such as the ability to target"undrug-gable"proteins,prolonged pharmacological effects,and the potential to overcome drug resistance.To date,a number of PROTACs have progressed to the clinical research stage,showing promising therapeutic potential in oncology and immunology.This review summarizes the mechanisms of action,unique advantages,current research status and recent progress of PROTACs,aiming to pro-vide insights for the future research and development of PROTAC drugs.关键词
蛋白降解靶向嵌合体/泛素-蛋白酶体系统/蛋白质降解Key words
Proteolysis-targeting chimera/Ubiquitin-proteasome system/Protein degradation分类
医药卫生引用本文复制引用
陈泉霖,朱蕾..蛋白降解靶向嵌合体药物研究新进展[J].医药导报,2026,45(6):1009-1014,6.基金项目
中国医学科学院医学与健康科技创新工程(2021-I2M-1-005,2025-I2M-KJ-009) （2021-I2M-1-005,2025-I2M-KJ-009）
北京协和医院中央高水平医院临床科研专项(2022-PUMCH-C-025). （2022-PUMCH-C-025）
